v3.26.1
Segment Information - Schedule of Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total revenue $ 9,238   $ 11,489   $ 26,193 $ 21,378
Interest income (268)   (542)   (622) (836)
Interest expense 2,705   2,744   5,460 5,490
Remeasurement of warrant liability (1,602)   0   (1,602) 0
Remeasurement of derivative liability (4,113)   0   (4,113) 0
Gain on debt extinguishment (43,846)   0   (43,846) 0
Other income, net 4,150   (2,694)   3,547 (5,318)
Segment net gain (loss) 16,900 $ (46,664) (38,273) $ (36,638) (29,764) (74,911)
Reporting Segment            
Segment Reporting [Line Items]            
Total revenue 9,238   11,489   26,193 21,378
Seralutinib 25,914   41,575   68,264 79,616
Other segment items 9,398   8,679   28,869 17,337
Interest income (268)   (542)   (622) (836)
Interest expense 2,705   2,744   5,460 5,490
Remeasurement of warrant liability (1,602)   0   (1,602) 0
Remeasurement of derivative liability (4,113)   0   (4,113) 0
Gain on debt extinguishment (43,846)   0   (43,846) 0
Other income, net 4,150   (2,694)   3,547 (5,318)
Segment net gain (loss) $ 16,900   $ (38,273)   $ (29,764) $ (74,911)